Results 11 to 20 of about 36,486 (260)

The introduction of a novel formulation of buprenorphine into organized health systems

Drug and Alcohol Dependence Reports, 2022
Background: Effective medications for opioid use disorder (MOUD) are underutilized. This exploratory study used real-world data to analyze US distribution patterns of buprenorphine extended-release (BUP-XR) within organized health systems (OHS ...
William Mullen, Michaela Hedberg, Brian Gadbois, Christian Heidbreder   +3 more
doaj   +1 more source

Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder

Contemporary Clinical Trials Communications, 2021
Background: Opioid use disorder (OUD) negatively impacts the HIV continuum of care for persons living with HIV. Medication treatment for OUD (MOUD) may have differential biological effects in individuals with HIV and OUD.
Breanne E. Biondi, Subhasis Mohanty, Brent Vander Wyk, Ruth R. Montgomery, Albert C. Shaw, Sandra A. Springer   +5 more
doaj   +1 more source

Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study

Addiction Science & Clinical Practice, 2022
Background Medication for opioid use disorder (MOUD) reduces mortality, but few patients access MOUD. At a Federally Qualified Health Center (FQHC), we implemented a low barrier model of MOUD, including same-day MOUD initiation and a harm reduction ...
Jamie Carter, Zhen Li, Hillary Chen, Melissa Greiner, Christopher Bush, Debanjan Bhattacharya, Stephanie Poley, Nidhi Sachdeva, Jane Carolyn Crowder, Jacob Feigal   +9 more
doaj   +1 more source

Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorder

Drug and Alcohol Dependence Reports, 2022
Introduction: Psychosocial support is recommended in conjunction with medication for opioid use disorder (MOUD), although optimal “dose,” modality, and timing of participation is not established.
Kathryn Hefner, Tse-Hwei Choo, Dikla Shmueli-Blumberg, Martina Pavlicova, Jacquie King, Marc Fishman, Matisyahu Shulman, Aimee Campbell, Miranda Greiner, Jennifer Scodes, Sarah Meyers-Ohki, Patricia Novo, Edward Nunes, John Rotrosen   +13 more
doaj   +1 more source

Medication-Assisted Treatment for Opioid-Use Disorder [PDF]

Mayo Clinic Proceedings, 2019
The United States is in the midst of a national opioid epidemic. Physicians are encouraged both to prevent and treat opioid-use disorders (OUDs). Although there are 3 Food and Drug Administration-approved medications to treat OUD (methadone, buprenorphine, and naltrexone) and there is ample evidence of their efficacy, they are not used as often as they
Tyler S. Oesterle, Nuria J. Thusius, Teresa A. Rummans, Mark S. Gold   +3 more
openaire   +2 more sources

Baseline Characteristics and Postdischarge Outcomes by Medication for Opioid Use Disorder Status Among Women with Polysubstance Use in Residential Treatment

Women's Health Reports, 2023
Background: Within residential treatment, medication for opioid use disorder (MOUD) is rarely offered, so little is known about group differences by MOUD status.
Anna Beth Parlier-Ahmad, Sydney Kelpin, Caitlin E. Martin, Dace S. Svikis   +3 more
doaj   +1 more source

Advancing emergency department–initiated buprenorphine

Journal of the American College of Emergency Physicians Open, 2021
Opioids are the main driver of drug overdose deaths in the United States, and there has been a marked increase in opioid‐related overdoses during the COVID‐19 public health emergency.
Kristen Huntley, Emily Einstein, Terri Postma, Anita Thomas, Shari Ling, Wilson Compton   +5 more
doaj   +1 more source

Prescribers’ satisfaction with delivering medications for opioid use disorder [PDF]

Substance Abuse Treatment, Prevention, and Policy, 2021
Abstract Background Expanding access to medications for opioid use disorder (MOUD), such as buprenorphine and extended release (XR) naltrexone, is critical to addressing the US opioid epidemic, but little is known about prescriber satisfaction with delivering these two types of MOUD.
Knudsen, Hannah K, Brown, Randy, Jacobson, Nora, Horst, Julie, Kim, Jee-Seon, Kim, Hanna, Madden, Lynn M, Haram, Eric, Molfenter, Todd   +8 more
openaire   +5 more sources

Medications for management of opioid use disorder

American Journal of Health-System Pharmacy, 2019
Abstract Purpose The use of buprenorphine, methadone, and long-acting naltrexone for treatment of opioid use disorder (OUD) is discussed, including a review of current literature detailing treatment approaches and action steps to optimize treatment in acute care and office-based settings.
Jennifer L, Koehl, David E, Zimmerman, Patrick J, Bridgeman   +2 more
openaire   +2 more sources

Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021

JAMA Network Open, 2023
This cross-sectional study uses data from the 2021 National Survey on Drug Use and Health to estimate the receipt of medication for opioid use disorder among US adults with past-year opioid use disorder.
Jones, Christopher M., Han, Beth, Baldwin, Grant T., Einstein, Emily B., Compton, Wilson M.   +4 more
openaire   +2 more sources